In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to establish Harmless dosing regimen. Added contributors will likely be enrolled within the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 might be given as "incorporate-on" therapy. In Section C, https://abbv-744brd4inhibitormech02457.tkzblog.com/31794677/abbv-744-in-combination-with-immunotherapy-an-overview